Nexstim Abp licensierar ut teknik till det amerikanska medicinteknikföretaget Magnus Medical, Inc. för behandling av neuropsykiatriska tillstånd
February 14, 2022 02:00 ET
|
Nexstim Oyj
Företagsmeddelande, insiderinformation, Helsingfors 14.2.2022 kl. 9.00 (EET) Nexstim Abp licensierar ut teknik till det amerikanska medicinteknikföretaget Magnus Medical, Inc. för behandling av...
Nexstim Plc to license technology to US-based medical technology company Magnus Medical, Inc. for the treatment of neuropsychiatric disorders
February 14, 2022 02:00 ET
|
Nexstim Oyj
Company Announcement, Inside Information, Helsinki, 14 February 2022, at 9 AM (EET) Nexstim Plc to license technology to US-based medical technology company Magnus Medical, Inc. for the treatment of...
Nexstim har kommit överens om en strategisk investering i en Management Services-organisation för en Kalifornien-baserad klinik som tillhandahåller behandlingar för depressionspatienter
November 22, 2021 02:00 ET
|
Nexstim Oyj
Företagsmeddelande, insiderinformation, Helsingfors, 22.11.2021 kl. 9.00 (EET) Nexstim har kommit överens om en strategisk investering i en Management Services-organisation för en Kalifornien-baserad...
Nexstim on sopinut strategisesta investoinnista masennuspotilaille hoitoja tarjoavaan kalifornialaisen klinikan palveluyhtiöön
November 22, 2021 02:00 ET
|
Nexstim Oyj
Yhtiötiedote, sisäpiiritieto, Helsinki, 22.11.2021 klo 9.00 (EET) Nexstim on sopinut strategisesta investoinnista masennuspotilaille hoitoja tarjoavaan kalifornialaisen klinikan palveluyhtiöön ...
Nexstim Agrees on a Strategic Investment into a Management Services Organisation of a California Based Clinic Providing Treatments for Depression Patients
November 22, 2021 02:00 ET
|
Nexstim Oyj
Company Announcement, Inside information, Helsinki, 22.11.2021 at 9 AM (EET) Nexstim Agrees on a Strategic Investment into a Management Services Organisation of a California Based Clinic Providing...
Axsome Therapeutics Provides Update on the New Drug Application for AXS-05 for the Treatment of Major Depressive Disorder
August 23, 2021 06:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
Axsome Therapeutics Announces Positive Efficacy and Safety Results from Phase 3 COMET Long-Term Trial and COMET-AU Trial of AXS-05 in Major Depressive Disorder
December 01, 2020 06:00 ET
|
Axsome Therapeutics, Inc.
Rapid and substantial improvement in depressive symptoms achieved by 40% of patients at 2 weeks, 73% at 6 weeks (MADRS response), and sustained over 12 months Rapid and substantial improvement in...
Axsome Therapeutics and Veeva Systems Partner to Build Axsome’s Digital-Centric Commercialization™ Platform
November 04, 2020 07:03 ET
|
Axsome Therapeutics, Inc.
Collaboration provides Axsome access to new digital technologies developed by Veeva NEW YORK and PLEASANTON, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...
Axsome Therapeutics Presents New Data from GEMINI Phase 3 Trial with AXS-05 Demonstrating Rapid and Significant Improvements in Patient-Reported Outcomes in Major Depressive Disorder
September 14, 2020 06:00 ET
|
Axsome Therapeutics, Inc.
Rapid, durable, and statistically significant improvement demonstrated in patient-reported depressive symptoms, as measured by the QIDS-SR-16 total score compared to placebo (p=0.001) Clinical...
Axsome Therapeutics Announces Further Progress in AXS-05 Depression Clinical Program
August 10, 2020 07:00 ET
|
Axsome Therapeutics, Inc.
Enrollment complete in the COMET Phase 3 long-term safety trial of AXS-05 in MDD; NDA filing on track for 4Q 2020 Results from three Phase 2 open-label efficacy trials of AXS-05 in TRD,...